Merck names Michael Holston as future general counsel Merck announced the future appointment of Michael J. Holston as general counsel, effective July 1, 2015. Holston, who will also oversee responsibility for Merck’s communications, policy and security organizations beginning July 1 of this year, will succeed Bruce N. Kuhlik upon his retirement after ten years with the company. Holston will remain in his role as chief ethics and compliance officer during the transition period. These changes reflect a multi-year executive succession planning process.
News For MRK From The Last 14 Days
Check below for free stories on MRK the last two weeks.
FDA approves Belsomra sleep drug The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.